Evidence-Based Evaluation on Off-Label Drug Use Policies in 15 Countries
ZHANG Ling-li,LI You-ping,ZENG Li-nan,LIANG Yi,HU Die,LIU Yi,LV Juan
DOI: https://doi.org/10.3969/j.issn.1672-2531.2012.04.010
2012-01-01
Abstract:Objective To evaluate the related laws,regulations and guidelines about off-label drug use in several countries,so as to provide evidence for regulating off-label drug use in China.Methods The following 3 Chinese databases as CBM,CNKI and VIP,11 foreign databases including EMbase,PubMed and so on,15 countries' official websites of pharmaceutical administration department or academic organization,and WHO website were searched to obtain the related laws,regulations and guidelines about off-label drug use.By adopting the system evaluation method and self-defined index evaluation,the quality of the included literatures was evaluated in three aspects: literatures' type,content relevance and timeliness.Seven researchers independently extracted data by Excel which included basic information of literatures,preconditions of off-label drug use,medicines categories that could be off-labelly used,regulations and legal responsibility in off-label drug use.And finally the descriptive analysis was conducted.Results A total of 4 735 literatures were retrieved,104 of which were finally included,including 89 at grade A quality level(85.58%) and 15 was at grade B(14.42%).The analysis showed that,a) Seven countries had laws related to off-label drug use: America,Germany,Italy,Netherland,New Zealand,India and Japan.Except India,the rational off-label drug use was allowed in the other 6 countries.The right to prescribe off-label drug was defined in Britain and Ireland;b) Medical staff had to take the responsibility of off-label drug use in the country where the duty regulations were formulated;and c) Ten countries published guidelines or statements related to off label drug use by their official departments and academic organizations.And the regulation included the following procedures: firstly,to obtain the relative information and evidence;secondly,to get the informed consent;thirdly,to be approved by the ethics committee and/or pharmacy administration committee;fourthly,to record the reasons and effectiveness of off-label use;fifthly,to monitor the adverse reactions of off-label drug use.Besides monitoring the medical institutes,the pharmaceutical companies had also be monitored which included the following 3 aspects: a) to require companies to train specialized staffs to answer the questions related to off-label drug use;b) to open the contact information of medical departments of companies;and c) to prohibit preaching and advertising the off-label drug use.Conclusion Off-label drug use has its rationality and necessity.To protect the safety of patients,avoid the risk for hospitals and medical staffs,it requires formulating relative regulations soon in order to manage the off-label drug use in China.As a developing country,China is different from the developed countries in health care system.Therefore,when formulating the regulations,it is necessary to perform evidence-based evaluation on each country's laws,regulations and guidelines about off-label drug use,with Chinese national conditions and experts' opinions in combination.After a regulation is preliminarily drawn up,it needs to be put into pilot practice,and then revised and spread to the whole country.